Scholarlink

Background <p>This case report illustrates the effective management of disseminated histoplasmosis-induced secondary hemophagocytic lymphohistiocytosis using intravenous liposomal amphotericin B and prednisone in a patient undergoing long-term treatment for rheumatoid arthritis with immunosuppressive medications.</p> Case presentation <p>A 57-year-old immunocompromised male presented with fevers, chills, myalgias, and pancytopenia. He received a diagnosis of disseminated histoplasmosis and met criteria for secondary hemophagocytic lymphohistiocytosis. Treatment with intravenous liposomal amphotericin B and prednisone proved successful. Following significant clinical improvement within two weeks, he transitioned to oral itraconazole with plans for a twelve-month continuation.</p> Conclusion <p>Many uncertainties remain regarding the optimal management of secondary hemophagocytic lymphohistiocytosis in the context of disseminated histoplasmosis, particularly regarding the utilization of immunosuppressive therapy and intravenous immunoglobulin. Currently, the decision to employ immunosuppression should be tailored to each patient’s unique clinical scenario.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Secondary hemophagocytic lymphohistiocytosis to disseminated histoplasmosis in the setting of chronic immunosuppression

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月9日

查看全文
  • Marla Rodriguez,
  • Ashruta Patel

摘要

Background

This case report illustrates the effective management of disseminated histoplasmosis-induced secondary hemophagocytic lymphohistiocytosis using intravenous liposomal amphotericin B and prednisone in a patient undergoing long-term treatment for rheumatoid arthritis with immunosuppressive medications.

Case presentation

A 57-year-old immunocompromised male presented with fevers, chills, myalgias, and pancytopenia. He received a diagnosis of disseminated histoplasmosis and met criteria for secondary hemophagocytic lymphohistiocytosis. Treatment with intravenous liposomal amphotericin B and prednisone proved successful. Following significant clinical improvement within two weeks, he transitioned to oral itraconazole with plans for a twelve-month continuation.

Conclusion

Many uncertainties remain regarding the optimal management of secondary hemophagocytic lymphohistiocytosis in the context of disseminated histoplasmosis, particularly regarding the utilization of immunosuppressive therapy and intravenous immunoglobulin. Currently, the decision to employ immunosuppression should be tailored to each patient’s unique clinical scenario.